Predictive role of ABC transporters in the efficacy of enfortumab vedotin for urothelial carcinoma
BJUI Compass · 2025-01 · 6 (1)
DOI: 10.1002/bco2.488 ↗Kurz gefasst
Fachartikel in der Zeitschrift BJUI Compass, online erschienen am 11.01.2025. Verfasst von Toshiki Kijima und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology Dokkyo Medical University Tochigi Japan. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Society for the Promotion of Science.
Abstract (Originalsprache)
Objective
To evaluate the correlation between ATP‐binding cassette (ABC) transporter expression and therapeutic efficacy of enfortumab vedotin (EV), an antibody‐drug conjugate targeting Nectin‐4, in urothelial cancer, as only a few studies have been conducted on this topic. Patients and methods This retrospective study included 20 patients with metastatic urothelial carcinoma (mUC), including bladder and upper urinary tract cancers, who were treated with EV at Dokkyo Medical University Hospital between 2022 and 2024. Immunohistochemical staining was performed on formalin‐fixed, paraffin‐embedded tissue samples. Progression‐free survival (PFS) was estimated using the Kaplan–Meier method, and differences between subgroups (e.g., Nectin‐4 and ABC transporter expression) were compared using the log‐rank test.
Results
Immunohistochemical analysis indicated that tumours with high ABC transporter expression exhibited shorter PFS time and poorer response to EV. Furthermore, a decrease in Nectin‐4 expression and an increase in ABC transporter expression were observed as the disease progressed from non‐muscle‐invasive to muscle‐invasive and metastatic. Patients with Nectin‐4‐positive and ABC transporter‐negative tumours had the longest PFS, underscoring the prognostic significance of these biomarkers.
Conclusion
To our knowledge, this study is the first to show a correlation between ABC transporter expression and EV efficacy in urothelial carcinoma. Future research should focus on optimizing treatment strategies based on Nectin‐4 and ABC transporter expression to improve outcomes.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Urology Dokkyo Medical University Tochigi Japan.
- Department of Diagnostic Pathology Dokkyo Medical University Tochigi Japan.
- Department of Urology Tokyo Medical and Dental University, Dokkyo Medical University Tokyo Japan.
ORCID-Profile: Toshiki Kijima, Takao Kamai
Förderung
- Japan Society for the Promotion of Science
Zitieren
APA
Kijima, T., Takada-Owada, A., Shimoda, H., Kokubun, H., Uematsu, T., Takei, K., Betsunoh, H., Yashi, M., Ishida, K., & Kamai, T. (2025). Predictive role of ABC transporters in the efficacy of enfortumab vedotin for urothelial carcinoma. BJUI Compass, 6(1). https://doi.org/10.1002/bco2.488
Vancouver
Kijima T, Takada-Owada A, Shimoda H, Kokubun H, Uematsu T, Takei K, et al. Predictive role of ABC transporters in the efficacy of enfortumab vedotin for urothelial carcinoma. BJUI Compass. 2025;6(1). doi:10.1002/bco2.488
BibTeX
@article{Kijima2025,
author = {Kijima, Toshiki and Takada-Owada, Atsuko and Shimoda, Hiroki and Kokubun, Hidetoshi and Uematsu, Toshitaka and Takei, Kohei and Betsunoh, Hironori and Yashi, Masahiro and Ishida, Kazuyuki and Kamai, Takao},
title = {Predictive role of ABC transporters in the efficacy of enfortumab vedotin for urothelial carcinoma},
journal = {BJUI Compass},
year = {2025},
volume = {6},
number = {1},
doi = {10.1002/bco2.488}
}
EUVIMED